Lyell Immunopharma, Inc. — Proxy Solicitation & Information Statement 2024

Apr 22, 2024

DEFA14A 1 ny20023138x2_defa14a.htm DEFA14A Licensed to: Broadridge Financial Solutions, Inc. Document created using Broadridge PROfile 24.3.1.5224 Copyright 1995 - 2024 Broadridge

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No. )

Filed by the Registrant	​☒	​
Filed by a Party other than the Registrant	​ ☐	​

Check the appropriate box:

☐	​	​	Preliminary Proxy Statement
☐	​	​	Confidential, for Use of the Commission Only (as permitted by Rule
14a-6(e)(2))
☐	​	​	Definitive Proxy Statement
☒	​	​	Definitive Additional Materials
☐	​	​	Soliciting Material Pursuant to § 240.14a-12

LYELL IMMUNOPHARMA, INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

☒	​	​	No fee required
☐	​	​	Fee paid previously with preliminary materials
☐	​	​	Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11